Company Encyclopedia
View More
name
SYNERGY
300636.SZ
Jiangxi Synergy Pharmaceutical Co., Ltd. manufactures and sells APIs worldwide. It offers raw materials, pharmaceutical intermediates, and fine chemicals. Jiangxi Synergy Pharmaceutical Co., Ltd.
3.159 T
300636.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking162/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.03%C
    • Profit Margin11.45%B
    • Gross Margin42.22%B
  • Growth ScoreC
    • Revenue YoY12.67%B
    • Net Profit YoY-23.20%D
    • Total Assets YoY-1.11%D
    • Net Assets YoY2.88%C
  • Cash ScoreB
    • Cash Flow Margin873.11%B
    • OCF YoY12.67%B
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreB
    • Gearing Ratio27.09%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SYNERGY passed the on-site inspection by the U.S. FDA

    SYNERGY underwent a cGMP on-site inspection by the U.S. FDA from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. The company recently confirmed that it has passed the inspection and complies with the U.S. FDA's cGMP management standards

    Zhitong·
    SZ
    300636
    0.00%
    Zhitong·
    SZ
    300636
    0.00%

    SYNERGY has obtained the European Pharmacopoeia Adaptation Certificate

    According to the Zhitong Finance APP, SYNERGY announced that the company recently received the revised Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor issued by the European Directorate for the Quality of Medicines (EDQM). The main reason for this change is the addition of a new production workshop, and the certification scope is: Ticagrelor active pharmaceutical ingredient. The revised certificate will take effect from September 12, 2025

    Zhitong·
    SZ
    300636
    0.00%
    Zhitong·
    SZ
    300636
    0.00%

    SYNERGY: CMO/CDMO business is expected to achieve rapid growth in 2027 and 2028

    SYNERGY stated in an institutional survey that the company's CMO/CDMO business saw growth in the second quarter, with promising prospects for the future. In recent years, the company has added more projects in the CMO/CDMO sector. As some older projects gradually exit the market, the company will actively serve existing projects and vigorously explore new projects, striving for new projects to ramp up production as soon as possible to make up for the gap caused by the decrease in orders from existing older projects. The CMO/CDMO business is expected to achieve rapid growth in 2027 and 2028

    Zhitong·
    SZ
    300636
    0.00%
    Zhitong·
    SZ
    300636
    0.00%

    SYNERGY: The raw material drug Amlodipine Besylate has passed the GMP compliance inspection

    SYNERGY announced that its raw material drug, Mesalazine Potassium, has passed the GMP compliance inspection, which is beneficial for the company to expand the sales of its products in the domestic market, forming a good pattern of simultaneous sales in both domestic and foreign markets. Mesalazine Potassium is suitable for the treatment of adult primary hypertension

    Zhitong·
    SZ
    300636
    0.00%
    Zhitong·
    SZ
    300636
    0.00%

    SYNERGY: Agomelatine and Opicapone have obtained drug registration certificates in South Korea

    According to the Zhitong Finance APP, SYNERGY announced that the company recently received the drug registration certificates for Agomelatine and Opicapone issued by the Ministry of Food and Drug Safety (MFDS) of South Korea

    Zhitong·
    SZ
    300636
    0.00%
    Zhitong·
    SZ
    300636
    0.00%
    © 2025 Longbridge｜Disclaimer